<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer Res Clin Oncol</journal-id><journal-title-group><journal-title>Journal of Cancer Research and Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0171-5216</issn><issn pub-type="epub">1432-1335</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">716</article-id><article-id pub-id-type="doi">10.1007/s00432-009-0716-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kolwijck</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massuger</surname><given-names>Leon F. A. G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Chris M. G.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Span</surname><given-names>Paul N.</given-names></name><address><phone>+31-243616845</phone><fax>+31-243568350</fax><email>P.Span@rther.umcn.nl</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Krasovec</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kos</surname><given-names>Janko</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sweep</surname><given-names>Fred C. G. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands </aff><aff id="Aff4"><label>4</label>Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia </aff><aff id="Aff5"><label>5</label>Department of Biotechnology, Jo&#x0017e;ef Stefan Institute, Ljubljana, Slovenia </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>11</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2010</year></pub-date><volume>136</volume><issue>5</issue><fpage>771</fpage><lpage>778</lpage><history><date date-type="received"><day>23</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="en"><sec><title>Introduction</title><p>In cancer, an extracellular and membrane bound localization of cathepsins contribute to the invasion of tumor cells at the basement membrane.</p></sec><sec><title>Methods</title><p>This is the first study that explored levels of cathepsins B (CatB), L (CatL) and their inhibitor cystatin C (CysC) in the cystic fluid (CF) of ovarian tumors (<italic>n</italic>&#x000a0;=&#x000a0;110).</p></sec><sec><title>Results</title><p>CF contained considerable amounts of CatB, CatL and CysC. Remarkable differences in CatB and CatL and CysC CF levels were found between different histopathological tumor subtypes. Levels of CatB and CysC were significantly higher in CF of malignant serous tumors compared to those found in benign serous tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.010 and <italic>p</italic>&#x000a0;=&#x000a0;0.001 respectively), whereas levels of CatL were significantly higher in CF of malignant mucinous tumors compared to those found in benign mucinous tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.035). CatB and CysC showed a strong correlation in the group of patients with malignant serous tumors (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; <italic>R</italic>&#x000a0;=&#x000a0;0.921) suggesting that the increase in CatB might be balanced by a corresponding increase in CysC.</p></sec><sec><title>Conclusion</title><p>Further studies are warranted to investigate cathepsins as possible prognostic biomarkers for the aggressiveness of ovarian cancer.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Ovarian cancer</kwd><kwd>Cathepsin</kwd><kwd>Cystatin</kwd><kwd>Cyst fluid</kwd><kwd>Ovarian tumor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Because of the absence of early symptoms, approximately 70% of the patients are diagnosed with FIGO stage III or IV, when tumor cells already have metastasized to the upper abdomen (Colombo et al. <xref ref-type="bibr" rid="CR8">2006</xref>). Compared to other types of cancer, insight into the carcinogenesis and progression of ovarian cancer is limited by the lack of a well-defined precursor lesion and by the lack of data from early-stage cancers (Landen et al. <xref ref-type="bibr" rid="CR21">2008</xref>).</p><p>In neoplastic transformation, the epithelial surface first becomes multicell layered. Tumor cells then degrade the basement membrane and invade the stroma or become detached from the primary tumors and metastasize (Capo-Chichi et al. <xref ref-type="bibr" rid="CR3">2002</xref>; Scully <xref ref-type="bibr" rid="CR35">1995</xref>; Feeley and Wells <xref ref-type="bibr" rid="CR10">2001</xref>; Aznavoorian et al. <xref ref-type="bibr" rid="CR1">1993</xref>). It is now widely believed that the degradation of the basement membrane is catalyzed by proteolytic enzymes (Liotta et al. <xref ref-type="bibr" rid="CR25">1980</xref>; Turk et al. <xref ref-type="bibr" rid="CR41">2000</xref>; Duffy <xref ref-type="bibr" rid="CR9">1996</xref>). Among these enzymes are the lysosomal cysteine proteinases or cathepsins, which have an important physiological function in regulation of intracellular protein metabolism. The human family of cathepsins has 11 members (cathepsin B, C, F, H, K, L, O, S, V, W and X), which share a conserved active site that is formed by cysteine, histidine and asparagine residues. In cancer tissue, an increased expression of cathepsins has been described and an extracellular and membrane-bound localization of particularly cathepsin B (CatB) and cathepsin L (CatL) has been demonstrated, which might contribute to the invasion of tumor cells at the basement membrane (Turk et al. <xref ref-type="bibr" rid="CR41">2000</xref>; Kos et al. <xref ref-type="bibr" rid="CR18">2000</xref>; Premzl et al. <xref ref-type="bibr" rid="CR33">2006</xref>).</p><p>Numerous reports have now been published investigating cancer tissue expression of cathepsins (Duffy <xref ref-type="bibr" rid="CR9">1996</xref>; Schwartz <xref ref-type="bibr" rid="CR34">1995</xref>; Sloane et al. <xref ref-type="bibr" rid="CR37">1990</xref>). Although quantitation of cathepsins in extracellular fluid has several advantages compared to measurement in tissue, reports investigating extracellular cathepsin levels are rather limited (Kos et al. <xref ref-type="bibr" rid="CR18">2000</xref>). Higher levels of CatB and CatL were reported in sera of patients with several types of cancer (Gabrijelcic et al. <xref ref-type="bibr" rid="CR11">1992</xref>; Kos et al. <xref ref-type="bibr" rid="CR16">1997</xref>, <xref ref-type="bibr" rid="CR17">1998</xref>; Leto et al. <xref ref-type="bibr" rid="CR22">1997a</xref>; Strojan et al. <xref ref-type="bibr" rid="CR39">2001</xref>; Zore et al. <xref ref-type="bibr" rid="CR45">2001</xref>; Bhuvarahamurthy and Govindasamy <xref ref-type="bibr" rid="CR2">1995</xref>), including ovarian cancer (Nishida et al. <xref ref-type="bibr" rid="CR30">1995</xref>; Warwas et al. <xref ref-type="bibr" rid="CR42">1997</xref>), compared to levels in healthy subjects or patients with benign lesions. The possibility of measuring cathepsins in blood increases its clinical value as a tumor marker, but reported levels in the serum are significantly lower than levels in tumor cells of cancer patients (Kos et al. <xref ref-type="bibr" rid="CR18">2000</xref>). Lah et al. (<xref ref-type="bibr" rid="CR19">1992</xref>) have shown that CatB was present in ascites of patients with ovarian carcinoma. Moreover, they showed that extracellular CatB was inhibited most strongly by cystatin C (CysC), which is an extracellular cysteine proteinase inhibitor (Lah et al. <xref ref-type="bibr" rid="CR19">1992</xref>). Recent studies on tissue of breast and ovarian cancer and melanoma showed that an imbalance of CatB/CysC (zonder levels) was correlated with a more aggressive tumor behavior (Kos et al. <xref ref-type="bibr" rid="CR16">1997</xref>; Nishikawa et al. <xref ref-type="bibr" rid="CR31">2004</xref>; Yano et al. <xref ref-type="bibr" rid="CR44">2001</xref>).</p><p>Most ovarian tumors exhibit, sometimes multiple, cysts that can be large. The cyst fluid (CF) is in close contact with the tumor tissue. To our knowledge, no studies have been performed to investigate the levels of cathepsins or their endogenous inhibitors in this ovarian CF. In the present study, we explored CatB, CatL as well as CysC levels in CF of patients with benign, borderline and malignant ovarian tumors.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients and cyst fluid collection</title><p>From our biobank containing ovarian cyst fluid (CF) samples of patients with ovarian tumors who underwent primary surgery at the Radboud University Nijmegen Medical Center in the period between 1988 and 1998, small portions of all 110 CF samples were retrieved. Samples in this biobank were collected by aseptic fine needle aspiration at the department of pathology immediately after surgical removal of the tumor. After cooled transport to the laboratory, the CF samples were centrifuged at 3,000&#x000d7;<italic>g</italic> for 10&#x000a0;min and the supernatant was stored at &#x02212;35&#x000b0;C in small portions until use. Histopathological diagnosis was performed by an experienced gynecologic pathologist and revealed 74 benign, 26 malignant and 10 borderline epithelial ovarian tumors. Informed consent was obtained from all participants.</p></sec><sec id="Sec4"><title>ELISA procedures</title><p>For the quantitative analysis of CatB, CatL and CysC in ovarian CF, commercially available specific ELISAs (sandwich ELISAs, Krka d.d., Novo mesto, Slovenia) were used, as developed by Kos et al. (<xref ref-type="bibr" rid="CR16">1997</xref>) at Jo&#x0017e;ef Stefan Institute, Ljubljana, Slovenia. The components were purified and characterized, and the tests were optimized and performed as described (Kos et al. <xref ref-type="bibr" rid="CR15">1995</xref>). To define the optimal dilution, CF samples were serially diluted to the levels encompassing the range of the assays. The linearity of the response was evaluated by comparing the measured values with the calibration curves. The recovery was tested by the addition of different amounts of the antigen to the samples with known antigen concentration that varied from 88 to 108%, comparing expected versus observed concentrations. The intra-assay coefficient of variance varied from 7.6 to 12.7%. CF samples were diluted 1:4 for CatB and CatL and 1:100 for CysC prior to being applied to the wells of microtiter plate. A microplate reader (SLT Rainbow, Salzburg, Austria) was used to measure absorbance. Determination of the levels of cathepsins and CysC was carried out without prior knowledge of the histological or clinical outcome.</p></sec><sec id="Sec5"><title>Parameters for aggressiveness of the tumor</title><p>From the pathology and medical reports of the patients with EOC, the following parameters were retrieved: histopathologic subtype and histopathologic grade, age at diagnosis and FIGO stage of disease. Histopathologic subtype and tumor grade were classified according to the World Health Organization (WHO) criteria (Servov et al. (<xref ref-type="bibr" rid="CR36">1973</xref>)). Staging was performed using the International Federation of Gynaecologists and Obstetricians (FIGO) criteria (Pecorelli et al. <xref ref-type="bibr" rid="CR32">1999</xref>). In case of uncertainty about the primary location of the tumor, extensive immunohistochemical staining was performed. Only patients with confirmed primary EOC were included.</p></sec><sec id="Sec6"><title>Statistical analyses</title><p>Values are shown as median with range (ng/ml). Normality of distributions was analyzed by Kolmogorov&#x02013;Smirnov testing. Data regarding CatB, CatL and CysC could be normalized by Ln transformation. Differences between two groups were tested by Student&#x02019;s <italic>t</italic> test, and for more than two groups by ANOVA and subsequent post hoc Tukey&#x02019;s HSD tests. Correlations were assessed by Pearson correlation tests of the Ln-transformed values. A priori significance was set at a two-sided <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05. All statistical analyses were performed using SPSS version 16.0.01 (SPSS Inc. Chicago IL, USA).</p></sec></sec><sec id="Sec7"><title>Results</title><p>The mean age at diagnosis was 40&#x000a0;years (SD&#x000a0;&#x000b1;&#x000a0;14) for patients with benign ovarian tumors (<italic>n</italic>&#x000a0;=&#x000a0;74), 42&#x000a0;years (SD&#x000a0;&#x000b1;&#x000a0;14) for patients with borderline ovarian tumors (<italic>n</italic>&#x000a0;=&#x000a0;10) and 57&#x000a0;years (SD&#x000a0;&#x000b1;&#x000a0;11) for patients with EOC (<italic>n</italic>&#x000a0;=&#x000a0;26). The mean age of patients with ovarian cancer was significantly higher than that of patients with benign (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, Student&#x02019;s <italic>t</italic> test) and borderline tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.009, Student&#x02019;s <italic>t</italic> test). No differences in mean age were found between patients with benign and borderline tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.898, Student&#x02019;s <italic>t</italic> test).</p><sec id="Sec8"><title>Histopathological subtype</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the median (range) concentrations of CatB, CatL and CysC in ovarian CF of patients with malignant, borderline and benign ovarian tumors, grouped by histological subtype. Within the benign group, CF levels of CatL were significantly different between serous cystadenomas and mucinous cystadenomas (<italic>p</italic>&#x000a0;=&#x000a0;0.003) and between endometriosis cysts and mucinous cystadenomas (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Although generally not significantly different from the other benign histological subtypes, the median concentrations of CatB and CatL in cystic endometriosis were remarkably high and comparable to those found in CF of malignant tumors. CysC concentrations were in the same range for all benign subclasses. Within the group of borderline and malignant tumors, CF levels of CatB, CatL and CysC did not differ significantly between histopathological subtypes.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#x000a0;=&#x000a0;110) grouped by histopathological subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Histology</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left">Cathepsin L</th><th align="left">Cystatin C</th></tr></thead><tbody><tr><td align="left">Benign</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Serous cystadenoma</td><td char="(" align="char">29 (39)</td><td char="(" align="char">12 (1&#x02013;269)</td><td char="(" align="char">31 (9&#x02013;121)<sup>a</sup></td><td char="(" align="char">572 (131&#x02013;1,781)</td></tr><tr><td align="left">&#x000a0;Mucinous cystadenoma</td><td char="(" align="char">21 (28)</td><td char="(" align="char">16 (1&#x02013;227)</td><td char="(" align="char">11 (1&#x02013;95)<sup>a, b</sup></td><td char="(" align="char">578 (39&#x02013;9,984)</td></tr><tr><td align="left">&#x000a0;Dermoid cyst</td><td char="(" align="char">5 (7)</td><td char="(" align="char">11 (1&#x02013;108)</td><td char="(" align="char">10 (2&#x02013;97)</td><td char="(" align="char">618 (117&#x02013;876)</td></tr><tr><td align="left">&#x000a0;Cystic endometriosis</td><td char="(" align="char">16 (22)</td><td char="(" align="char">71 (1&#x02013;177)</td><td char="(" align="char">69 (8&#x02013;233)<sup>b</sup></td><td char="(" align="char">338 (92&#x02013;1,931)</td></tr><tr><td align="left">&#x000a0;Corpus luteum cyst</td><td char="(" align="char">3 (4)</td><td char="(" align="char">18 (6&#x02013;98)</td><td char="(" align="char">15 (15&#x02013;133)</td><td char="(" align="char">644 (520&#x02013;1,805)</td></tr><tr><td align="left">Borderline</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Serous borderline tumor</td><td char="(" align="char">2 (20)</td><td char="(" align="char">14 (8&#x02013;21)</td><td char="(" align="char">28 (18&#x02013;38)</td><td char="(" align="char">1,449 (1,125&#x02013;1,772)</td></tr><tr><td align="left">&#x000a0;Mucinous borderline tumor</td><td char="(" align="char">6 (60)</td><td char="(" align="char">31 (2&#x02013;118)</td><td char="(" align="char">75 (8&#x02013;166)</td><td char="(" align="char">697 (474&#x02013;3,897)</td></tr><tr><td align="left">&#x000a0;Mixed-type borderline tumor*</td><td char="(" align="char">1 (10)</td><td char="(" align="char">227</td><td char="(" align="char">92</td><td char="(" align="char">340</td></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">1 (10)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Malignant</td><td char="(" align="char"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Serous cystadenocarcinoma</td><td char="(" align="char">10 (38)</td><td char="(" align="char">65 (3&#x02013;269)</td><td char="(" align="char">61 (8&#x02013;163)</td><td char="(" align="char">1,443 (448&#x02013;5,972)</td></tr><tr><td align="left">&#x000a0;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (31)</td><td char="(" align="char">33 (5&#x02013;269)</td><td char="(" align="char">31 (13&#x02013;187)</td><td char="(" align="char">959 (399&#x02013;9,984)</td></tr><tr><td align="left">&#x000a0;Endometrioid cystadenocarcinoma</td><td char="(" align="char">6 (23)</td><td char="(" align="char">85 (1&#x02013;269)</td><td char="(" align="char">71 (14&#x02013;181)</td><td char="(" align="char">1,200 (64&#x02013;2,907)</td></tr><tr><td align="left">&#x000a0;Mixed-type cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">95</td><td char="(" align="char">67</td><td char="(" align="char">1,232</td></tr><tr><td align="left">&#x000a0;Undifferentiated cystadenocarcinoma*</td><td char="(" align="char">1 (4)</td><td char="(" align="char">110</td><td char="(" align="char">75</td><td char="(" align="char">109</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>A single concentration is listed. Statistical significance according to ANOVA (<italic>p</italic>&#x000a0;=&#x000a0;0.001) with Tukey&#x02019;s HSD post hoc test of values normalized after Ln transformation</p><p><sup>a</sup><italic>p</italic>&#x000a0;=&#x000a0;0.003 for mucinous cystadenomas compared to serous cystadenomas</p><p><sup>b</sup><italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for mucinous cystadenomas compared to cystic endometriosis</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> show median (range) CF levels of CatB, CatL and CysC in benign (cystadenoma), borderline and malignant (cystadenocarcinoma) ovarian tumors according to the histopathological subtype. In serous tumors (<italic>n</italic>&#x000a0;=&#x000a0;41), CF levels of CatB were significantly higher for patients with malignant tumors compared to patients with benign tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.010), whereas CatL levels did not differ significantly within this histological subgroup. In contrast, in mucinous tumors (<italic>n</italic>&#x000a0;=&#x000a0;35), CF levels of CatL were significantly higher for patients with malignant tumors compared to patients with benign tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.035), whereas CatB levels did not differ within this histological subgroup. CF levels of CysC only differed between patients with malignant and benign tumors in the subgroup of serous tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.001).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in ovarian tumor cyst fluid (<italic>n</italic>&#x000a0;=&#x000a0;67) of benign, borderline and malignant tumors grouped by serous and mucinous subtype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Subtype</th><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value<sup>*</sup></th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value<sup>*</sup></th></tr></thead><tbody><tr><td align="left">Serous</td><td char="(" align="char">41</td><td align="left"/><td char="." align="char"><italic>0.031</italic></td><td align="left"/><td align="left">0.131</td><td align="left"/><td char="." align="char"><italic>0.001</italic></td></tr><tr><td align="left">&#x000a0;Serous cystadenoma</td><td char="(" align="char">29 (71)</td><td char="(" align="char">12 (1&#x02013;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">31 (9&#x02013;121)</td><td align="left"/><td char="(" align="char">572 (131&#x02013;1,780)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">&#x000a0;Serous borderline tumor</td><td char="(" align="char">2 (5)</td><td char="(" align="char">14 (8&#x02013;21)</td><td align="left"/><td char="(" align="char">28 (18&#x02013;38)</td><td align="left"/><td char="(" align="char">1,449 (1,125&#x02013;1,772)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Serous cystadenocarcinoma</td><td char="(" align="char">10 (24)</td><td char="(" align="char">65 (3&#x02013;269)<sup>a</sup></td><td align="left"/><td char="(" align="char">61 (8&#x02013;163)</td><td align="left"/><td char="(" align="char">1,443 (448&#x02013;5,972)<sup>b</sup></td><td align="left"/></tr><tr><td align="left">Mucinous</td><td char="(" align="char">35</td><td align="left"/><td char="." align="char">0.315</td><td align="left"/><td align="left"><italic>0.017</italic></td><td align="left"/><td char="." align="char">0.136</td></tr><tr><td align="left">&#x000a0;Mucinous cystadenoma</td><td char="(" align="char">21 (60)</td><td char="(" align="char">16 (1&#x02013;227)</td><td align="left"/><td char="(" align="char">11 (1&#x02013;95)<sup>c</sup></td><td align="left"/><td char="(" align="char">578 (39&#x02013;9,984)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Mucinous borderline tumor</td><td char="(" align="char">6 (17)</td><td char="(" align="char">32 (2&#x02013;118)</td><td align="left"/><td char="(" align="char">75 (8&#x02013;166)</td><td align="left"/><td char="(" align="char">697 (474&#x02013;3,897)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Mucinous cystadenocarcinoma</td><td char="(" align="char">8 (23)</td><td char="(" align="char">33 (5&#x02013;269)</td><td align="left"/><td char="(" align="char">31 (13&#x02013;187)<sup>c</sup></td><td align="left"/><td char="(" align="char">959 (399&#x02013;9,984)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Statistical significance according to ANOVA</p><p>Student&#x02019;s <italic>t</italic> test<sup>a, b, c</sup> of values normalized after Ln transformation</p><p><sup>a</sup><italic>p</italic>&#x000a0;=&#x000a0;0.010 for serous cystadenoma compared to serous cystadenocarcinoma</p><p><sup>b</sup><italic>p</italic>&#x000a0;=&#x000a0;0.001 for serous cystadenoma compared to serous cystadenocarcinoma</p><p><sup>c</sup><italic>p</italic>&#x000a0;=&#x000a0;0.035 for mucinous cystadenoma compared to mucinous cystadenocarcinoma</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Box plots of the (<bold>a</bold>) cathepsin B and (<bold>b</bold>) cathepsin L, and (<bold>c</bold>) cystatin C (ng/ml) concentrations (logarithmic scale) in ovarian cyst fluid for patients with malignant, borderline and benign ovarian tumors, clustered by histological subtype (serous and mucinous tumors). Statistical significance above the subfigures are according to ANOVA (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) with Tukey&#x02019;s HSD post hoc tests of values normalized after Ln transformation</p></caption><graphic xlink:href="432_2009_716_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec9"><title>Parameters of aggressiveness of the tumor</title><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows clinicopathological parameters of tumor aggressiveness and median (range) concentrations of CatB, CatL and CysC of the 26 patients with EOC. Since no differences in CF levels of CatB, Cat L and CysC were found between serous, mucinous and endometrioid cystadenocarcinomas (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), data of patients with EOC were merged. When patients were grouped according to FIGO stage of disease, tumor grading and presence of ascites, no significant differences in CF levels of CatB, CatL and/or CysC were found.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Median levels (range) of cathepsin B, L and cystatin C (ng/ml) in malignant ovarian tumor cyst fluid (<italic>n</italic>&#x000a0;=&#x000a0;26) according to clinicopathological parameters for aggressiveness of the tumor</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>N</italic> (%)</th><th align="left">Cathepsin B</th><th align="left"><italic>p</italic>-value</th><th align="left">Cathepsin L</th><th align="left"><italic>p</italic>-value</th><th align="left">Cystatin C</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">FIGO stage</td><td align="left"/><td align="left"/><td char="." align="char">0.613<sup>a</sup></td><td align="left"/><td char="." align="char">0.984<sup>a</sup></td><td align="left"/><td char="." align="char">0.406<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Ia&#x02013;IIa</td><td char="[" align="char">13 (50)</td><td char="(" align="char">48 (28&#x02013;93)</td><td align="left"/><td char="(" align="char">40 (29&#x02013;78)</td><td align="left"/><td char="[" align="char">1,040 (594&#x02013;2,355)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02265;IIb</td><td char="[" align="char">12 (46)</td><td char="(" align="char">72 (16&#x02013;109)</td><td align="left"/><td char="(" align="char">63 (18&#x02013;125)</td><td align="left"/><td char="[" align="char">1,233 (1,055&#x02013;1,500)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="[" align="char">1 (4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Tumor grade</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.554<sup>b</sup></td><td align="left"/><td char="." align="char">0.595<sup>b</sup></td><td char="[" align="char"/><td char="." align="char">0.535<sup>b</sup></td></tr><tr><td align="left">&#x000a0;1</td><td char="[" align="char">6 (23)</td><td char="(" align="char">38 (10&#x02013;269)</td><td align="left"/><td char="(" align="char">31 (14&#x02013;187)</td><td align="left"/><td char="[" align="char">959 (465&#x02013;9,984)</td><td align="left"/></tr><tr><td align="left">&#x000a0;2</td><td char="[" align="char">5 (19)</td><td char="(" align="char">71 (38&#x02013;269)</td><td align="left"/><td char="(" align="char">62 (38&#x02013;163)</td><td align="left"/><td char="[" align="char">1,076 (399&#x02013;1,502)</td><td align="left"/></tr><tr><td align="left">&#x000a0;3</td><td char="[" align="char">13 (50)</td><td char="(" align="char">64 (3&#x02013;11)</td><td align="left"/><td char="(" align="char">64 (8&#x02013;181)</td><td align="left"/><td char="[" align="char">1,324 (448&#x02013;2,908)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="[" align="char">2 (8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td char="[" align="char"/><td align="left"/></tr><tr><td align="left">Ascites</td><td char="[" align="char"/><td align="left"/><td char="." align="char">0.632<sup>a</sup></td><td align="left"/><td char="." align="char">0.379<sup>a</sup></td><td char="[" align="char"/><td char="." align="char">0.569<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Yes</td><td char="[" align="char">11 (42)</td><td char="(" align="char">76 (5&#x02013;269)</td><td align="left"/><td char="(" align="char">64 (13&#x02013;181)</td><td align="left"/><td char="[" align="char">1,330 (1,048&#x02013;2,908)</td><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td char="[" align="char">12 (46)</td><td char="(" align="char">55 (10&#x02013;269)</td><td align="left"/><td char="(" align="char">48 (14&#x02013;187)</td><td align="left"/><td char="[" align="char">970 (399&#x02013;9,984)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="[" align="char">3 (12)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Statistical significance according to</p><p><sup>a</sup>Student&#x02019;s <italic>t</italic> test</p><p><sup>b</sup>ANOVA of values normalized after Ln transformation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Correlation between cathepsins and cystatin C</title><p>Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> shows the scatter plots of the correlation between Cathepsins and Cystatin C for patients with serous (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a and <xref rid="Fig2" ref-type="fig">2</xref>b; <italic>n</italic>&#x000a0;=&#x000a0;41) and mucinous (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c; <italic>n</italic>&#x000a0;=&#x000a0;35) tumors. For serous tumors, CF levels of CysC and CatB were significantly correlated (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>R</italic>&#x000a0;=&#x000a0;0.652, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). The correlation between CF levels of CysC and CatB was highest for the malignant group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>R</italic>&#x000a0;=&#x000a0;0.921). For mucinous tumors, CF levels of CysC and CatB did not show any relationship (<italic>p</italic>&#x000a0;=&#x000a0;0.923, figure not shown). Correlations between CF levels of CysC and CatL were significant for both serous and mucinous tumors (<italic>p</italic>&#x000a0;=&#x000a0;0.001, <italic>R</italic>&#x000a0;=&#x000a0;0.491, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b and <italic>p</italic>&#x000a0;=&#x000a0;0.003; <italic>R</italic>&#x000a0;=&#x000a0;0.481, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c, respectively). For mucinous tumors, the correlation between CF levels of CysC and CatL was highest for the benign group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>R</italic>&#x000a0;=&#x000a0;0.665).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Scatter plots of Ln-transformed values of cyst fluid cystatin C with cathepsin B (<bold>a</bold>) and cathepsin L (<bold>b</bold>) for patients with serous tumors (<italic>n</italic>&#x000a0;=&#x000a0;41) and cystatin C with cathepsin L (<bold>c</bold>) for patients with mucinous tumors (<italic>n</italic>&#x000a0;=&#x000a0;35). Statistical significance (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) and correlation coefficient (<italic>R</italic>) according to Pearson&#x02019;s correlation test. <italic>Asterisks</italic> malignant; <italic>open triangles</italic> borderline, <italic>open circles</italic> benign</p></caption><graphic xlink:href="432_2009_716_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec11"><title>Discussion</title><p>In this study, we examined ovarian CF levels of CatB, CatL and their extracellular inhibitor CysC. In benign tumors, remarkable differences in CF levels of cathepsins B and L were found between different histopathological subtypes. For serous tumors, the levels of CatB and CysC were significantly higher in the CF of patients with EOC compared to CF levels of patients with benign ovarian tumors. For mucinous tumors, the levels of CatL were significantly higher in the CF of patients with EOC compared to CF levels of patients with benign ovarian tumors. Furthermore, correlations between cyst fluid levels of CatB and CysC and between CatL and CysC were found. Finally, we investigated the relationship between the levels of CatB, CatL and CysC and parameters of tumor aggressiveness of EOC, but could not find significant differences between the subgroups of patients.</p><p>We are the first to describe that CF of ovarian tumors contains considerable amounts of CatB, CatL and CysC. In ascitic fluid of patients with ovarian cancer, Lah et al. (<xref ref-type="bibr" rid="CR19">1992</xref>) found CatB and a large pool of free CysC. We showed that CF levels of these enzymes were higher in ovarian cancer patients compared to patients with benign ovarian tumors. Serum studies in patients with other types of cancer have demonstrated similar results, as levels of CatB, CatL and CysC were found to be higher in serum of patients with cancer compared to serum levels of patients with benign tumors or healthy controls (Gabrijelcic et al. <xref ref-type="bibr" rid="CR11">1992</xref>; Kos et al. <xref ref-type="bibr" rid="CR16">1997</xref>, <xref ref-type="bibr" rid="CR17">1998</xref>; Leto et al. <xref ref-type="bibr" rid="CR22">1997a</xref>, <xref ref-type="bibr" rid="CR23">b</xref>; Strojan et al. <xref ref-type="bibr" rid="CR39">2001</xref>; Zore et al. <xref ref-type="bibr" rid="CR45">2001</xref>; Yano et al. <xref ref-type="bibr" rid="CR44">2001</xref>; Makarewicz et al. <xref ref-type="bibr" rid="CR26">1995</xref>; Miyake et al. <xref ref-type="bibr" rid="CR28">2004</xref>; Strojan et al. <xref ref-type="bibr" rid="CR40">2004</xref>; Mulaomerovic et al. <xref ref-type="bibr" rid="CR29">2007</xref>). In serum of patients with ovarian cancer, Warwas et al. (<xref ref-type="bibr" rid="CR42">1997</xref>) found higher levels of CatB compared to the levels in patients with benign ovarian tumors. On the other hand, Nishikawa et al. (<xref ref-type="bibr" rid="CR31">2004</xref>) could not observe a significant difference in serum CatB level between patients with benign ovarian tumors and ovarian cancer, although they did find a significantly higher level of CysC in the serum of patients with ovarian cancer. Only one study has been published investigating CatL in the serum of patients with ovarian tumors (Nishida et al. <xref ref-type="bibr" rid="CR30">1995</xref>). The authors found that the serum levels of CatL were elevated in 8/10 patients with ovarian cancer compared to 2/10 patients with benign ovarian tumors.</p><p>The mean age of patients with ovarian cancer is known to be significantly higher than that of patients with benign ovarian tumors (Merino and Jaffe <xref ref-type="bibr" rid="CR27">1993</xref>). This was also found in our study group. This might confound our results, as there is definite evidence that renal function decreases with age (Lindeman and Goldman <xref ref-type="bibr" rid="CR24">1986</xref>), which results in a reduced glomerular filtration rate in older people. CysC is known to be almost completely reabsorbed and catabolized in the proximal renal tubular cells (Stabuc et al. <xref ref-type="bibr" rid="CR38">2000</xref>). This might explain the higher serum levels of CysC that were reported earlier in patients with ovarian cancer compared to that in patients with benign ovarian tumors. However, we found no correlation in CF between age and CysC level within the subgroups of patients. In addition, it is unclear whether CysC levels in ovarian CF, in contrast to serum, are influenced by renal function. Finally, the group of patients with borderline tumors was of similar age as the patients with benign tumors, yet exhibited CatB, CatL and CysC levels similar to those of patients with ovarian cancer. The level of CysC might be changed also due to pathological renal failures, changing the glomerular filtration rate in cancer patients (Stabuc et al. <xref ref-type="bibr" rid="CR38">2000</xref>). However, patients included in this study, did not exhibit any impaired kidney function. Therefore, we believe that the results of CysC in this study have not been biased by age-related or pathological changes of kidney function.</p><p>Remarkably, CatB and CysC CF levels were significantly higher in malignant serous tumors compared to benign serous tumors, whereas CatL CF levels were significantly higher in malignant mucinous tumors compared to benign mucinous tumors. This finding contributes to the theory that malignant serous and mucinous ovarian tumors are different diseases, with subtype-specific biomarker profiles (Heinzelmann-Schwarz et al. <xref ref-type="bibr" rid="CR12">2006</xref>; Kobel et al. <xref ref-type="bibr" rid="CR14">2008</xref>; Cloven et al. <xref ref-type="bibr" rid="CR7">2004</xref>). In addition, a significant correlation between CatB and CysC was found for patients with serous tumors. Moreover, the correlation of CatB and CysC was extremely strong in the group of patients with malignant serous tumors (<italic>R</italic>&#x000a0;=&#x000a0;0.921), which might indicate that an increase of CF CatB in malignant tumors was balanced by a corresponding increase in CF CysC level. This finding could be interesting, as it was proposed in previous studies that a relative imbalance between CatB and CysC in patients with cancer might contribute to the invasion and metastasis of tumor cells (Kos et al. <xref ref-type="bibr" rid="CR18">2000</xref>; Nishikawa et al. <xref ref-type="bibr" rid="CR31">2004</xref>; Lah et al. <xref ref-type="bibr" rid="CR20">2000</xref>).</p><p>Although not significant, median CF levels of CatB and CatL were up to seven times higher in cystic endometriosis compared to the other histopathological subtypes, and levels were comparable to CF levels of ovarian cancer patients with unfavorable tumor characteristics. Noteworthy is that CysC did not differ between cystic endometriosis and other benign subtypes, which might suggest a different balance between CatB and CysC in endometriosis cysts compared to the other histological subtypes. This might be explained by the continuous breakdown of components of blood and stromal tissue in endometriosis without a malignant invasion or metastasis. However, it is now well established that endometriosis does have neoplastic potential and it has been associated with the development of endometrioid and clear-cell ovarian carcinoma (Feeley and Wells <xref ref-type="bibr" rid="CR10">2001</xref>; Wells <xref ref-type="bibr" rid="CR43">2004</xref>).</p><p>Since ovarian cancer tissue is highly heterogeneous, multiple biopsies are necessary for a careful examination (Hogdall et al. <xref ref-type="bibr" rid="CR13">2007</xref>; Chauhan et al. <xref ref-type="bibr" rid="CR4">2007</xref>). This means that quantitation of cathepsins and cystatins in biological fluids of ovarian cancer patients has several clinical advantages over measurements in ovarian cancer tissue. We found that the levels of cathepsins and CysC in ovarian CF were much higher than that in serum of cancer patients, as reported in literature. More specifically, up to six times more CatB was found in CF than in the serum of patients with colorectal carcinoma (Kos et al. <xref ref-type="bibr" rid="CR17">1998</xref>) and melanoma (Kos et al. <xref ref-type="bibr" rid="CR16">1997</xref>), up to ten times more CatL was found in ovarian CF than in serum of patients with ovarian cancer (Nishida et al. <xref ref-type="bibr" rid="CR30">1995</xref>), and up to eight times more CysC was found in ovarian CF than in the serum of patients with ovarian cancer (Nishikawa et al. <xref ref-type="bibr" rid="CR31">2004</xref>). This might indicate that CatB, CatL as well as CysC are released from tumor cells into the CF to a greater extent than the release of these compounds into the serum of cancer patients. In this way, CF values may give a better reflection of local changes of the ovarian tumor than levels of cathepsins and its inhibitors in serum, which also might be affected by the systemic response on malignant disease and circadian variations (Cimerman et al. <xref ref-type="bibr" rid="CR5">1999</xref>, <xref ref-type="bibr" rid="CR6">2000</xref>). From a clinical perspective, preoperative aspiration of ovarian cyst fluid might cause iatrogenic metastasis of tumor cells, and ovarian cyst fluid can only be used as a source of biomarkers for predicting prognosis and response to therapy. We, therefore, investigated the relationship between clinicopathological parameters that correspond with tumor aggressiveness and the levels of CatB, CatL and CysC in patients with ovarian cancer. However, when patients were grouped according to FIGO stage of disease, tumor grading and presence of ascites, no significant differences in CF levels of CatB, CatL and/or CysC were found. This could be caused by the relatively small size of cyst fluid samples from malignant tumors in the present study.</p></sec><sec id="Sec12"><title>Conclusions</title><p>CF levels of CatB, and its endogenous inhibitor CysC, were significantly higher in serous EOC compared to benign serous ovarian tumors, whereas CF levels of Cat L were significantly higher in mucinous EOC compared to benign mucinous ovarian tumors. The correlation between CatB and CysC was extremely strong for patients with serous EOC, which might indicate that an increase in CatB of these patients is balanced by a corresponding increase in CysC level. We feel that further studies with a larger series of samples from malignant tumors are needed to explore the possible prognostic value of cathepsins and CysC in ovarian CF.</p></sec></body><back><ack><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aznavoorian</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>AN</given-names></name><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name></person-group><article-title>Molecular aspects of tumor cell invasion and metastasis</article-title><source>Cancer</source><year>1993</year><volume>71</volume><issue>4</issue><fpage>1368</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19930215)71:4&#x0003c;1368::AID-CNCR2820710432&#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">8435813</pub-id></mixed-citation></ref><ref id="CR2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhuvarahamurthy</surname><given-names>V</given-names></name><name><surname>Govindasamy</surname><given-names>S</given-names></name></person-group><article-title>Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma</article-title><source>Mol Cell Biochem</source><year>1995</year><volume>144</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/BF00926738</pub-id><pub-id pub-id-type="pmid">7791743</pub-id></mixed-citation></ref><ref id="CR3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capo-Chichi</surname><given-names>CD</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Roland</surname><given-names>IH</given-names></name><name><surname>Vanderveer</surname><given-names>L</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>TC</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Xu</surname><given-names>XX</given-names></name></person-group><article-title>Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis</article-title><source>Cancer</source><year>2002</year><volume>95</volume><issue>8</issue><fpage>1802</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1002/cncr.10870</pub-id><pub-id pub-id-type="pmid">12365030</pub-id></mixed-citation></ref><ref id="CR4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>SC</given-names></name><name><surname>Vinayek</surname><given-names>N</given-names></name><name><surname>Maher</surname><given-names>DM</given-names></name><name><surname>Bell</surname><given-names>MC</given-names></name><name><surname>Dunham</surname><given-names>KA</given-names></name><name><surname>Koch</surname><given-names>MD</given-names></name><name><surname>Lio</surname><given-names>Y</given-names></name><name><surname>Jaggi</surname><given-names>M</given-names></name></person-group><article-title>Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy</article-title><source>J Histochem Cytochem</source><year>2007</year><volume>55</volume><issue>8</issue><fpage>867</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1369/jhc.7A7213.2007</pub-id><pub-id pub-id-type="pmid">17478446</pub-id></mixed-citation></ref><ref id="CR5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimerman</surname><given-names>N</given-names></name><name><surname>Brguljan</surname><given-names>PM</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Suskovic</surname><given-names>S</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera</article-title><source>Clin Chim Acta</source><year>1999</year><volume>282</volume><issue>1&#x02013;2</issue><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/S0009-8981(99)00008-X</pub-id><pub-id pub-id-type="pmid">10340450</pub-id></mixed-citation></ref><ref id="CR6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimerman</surname><given-names>N</given-names></name><name><surname>Brguljan</surname><given-names>PM</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Suskovic</surname><given-names>S</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Twenty-four hour variations of cystatin C and total cysteine proteinase inhibitory activity in sera from healthy subjects</article-title><source>Clin Chim Acta</source><year>2000</year><volume>291</volume><issue>1</issue><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/S0009-8981(99)00196-5</pub-id><pub-id pub-id-type="pmid">10612720</pub-id></mixed-citation></ref><ref id="CR7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cloven</surname><given-names>NG</given-names></name><name><surname>Kyshtoobayeva</surname><given-names>A</given-names></name><name><surname>Burger</surname><given-names>RA</given-names></name><name><surname>Yu</surname><given-names>IR</given-names></name><name><surname>Fruehauf</surname><given-names>JP</given-names></name></person-group><article-title>In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>2004</year><volume>92</volume><issue>1</issue><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2003.09.030</pub-id><pub-id pub-id-type="pmid">14751152</pub-id></mixed-citation></ref><ref id="CR8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Van</surname><given-names>GT</given-names></name><name><surname>Parma</surname><given-names>G</given-names></name><name><surname>Amant</surname><given-names>F</given-names></name><name><surname>Gatta</surname><given-names>G</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name></person-group><article-title>Ovarian cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2006</year><volume>60</volume><issue>2</issue><fpage>159</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2006.03.004</pub-id><pub-id pub-id-type="pmid">17018256</pub-id></mixed-citation></ref><ref id="CR9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MJ</given-names></name></person-group><article-title>Proteases as prognostic markers in cancer</article-title><source>Clin Cancer Res</source><year>1996</year><volume>2</volume><issue>4</issue><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">9816210</pub-id></mixed-citation></ref><ref id="CR10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feeley</surname><given-names>KM</given-names></name><name><surname>Wells</surname><given-names>M</given-names></name></person-group><article-title>Precursor lesions of ovarian epithelial malignancy</article-title><source>Histopathology</source><year>2001</year><volume>38</volume><issue>2</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2559.2001.01042.x</pub-id><pub-id pub-id-type="pmid">11207821</pub-id></mixed-citation></ref><ref id="CR11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrijelcic</surname><given-names>D</given-names></name><name><surname>Svetic</surname><given-names>B</given-names></name><name><surname>Spaic</surname><given-names>D</given-names></name><name><surname>Skrk</surname><given-names>J</given-names></name><name><surname>Budihna</surname><given-names>M</given-names></name><name><surname>Dolenc</surname><given-names>I</given-names></name><name><surname>Popovic</surname><given-names>T</given-names></name><name><surname>Cotic</surname><given-names>V</given-names></name><name><surname>Turk</surname><given-names>V</given-names></name></person-group><article-title>Cathepsins B, H and L in human breast carcinoma</article-title><source>Eur J Clin Chem Clin Biochem</source><year>1992</year><volume>30</volume><issue>2</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">1316176</pub-id></mixed-citation></ref><ref id="CR12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinzelmann-Schwarz</surname><given-names>VA</given-names></name><name><surname>Gardiner-Garden</surname><given-names>M</given-names></name><name><surname>Henshall</surname><given-names>SM</given-names></name><name><surname>Scurry</surname><given-names>JP</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>AN</given-names></name><name><surname>Bali</surname><given-names>A</given-names></name><name><surname>Vanden</surname><given-names>BP</given-names></name><name><surname>Baron-Hay</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name></person-group><article-title>A distinct molecular profile associated with mucinous epithelial ovarian cancer</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><issue>6</issue><fpage>904</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603003</pub-id><pub-id pub-id-type="pmid">16508639</pub-id></mixed-citation></ref><ref id="CR13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogdall</surname><given-names>EV</given-names></name><name><surname>Christensen</surname><given-names>L</given-names></name><name><surname>Kjaer</surname><given-names>SK</given-names></name><name><surname>Blaakaer</surname><given-names>J</given-names></name><name><surname>Kjaerbye-Thygesen</surname><given-names>A</given-names></name><name><surname>Gayther</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>IJ</given-names></name><name><surname>Hogdall</surname><given-names>CK</given-names></name></person-group><article-title>CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish &#x0201c;MALOVA&#x0201d; Ovarian Cancer Study</article-title><source>Gynecol Oncol</source><year>2007</year><volume>104</volume><issue>3</issue><fpage>508</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2006.09.028</pub-id><pub-id pub-id-type="pmid">17113137</pub-id></mixed-citation></ref><ref id="CR14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobel</surname><given-names>M</given-names></name><name><surname>Kalloger</surname><given-names>SE</given-names></name><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>McKinney</surname><given-names>S</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Palmer</surname><given-names>C</given-names></name><name><surname>Leung</surname><given-names>S</given-names></name><name><surname>Bowen</surname><given-names>NJ</given-names></name><name><surname>Ionescu</surname><given-names>DN</given-names></name><name><surname>Rajput</surname><given-names>A</given-names></name><name><surname>Prentice</surname><given-names>LM</given-names></name></person-group><article-title>Ovarian carcinoma subtypes are different diseases: implications for biomarker studies</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><issue>12</issue><fpage>e232</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050232</pub-id><pub-id pub-id-type="pmid">19053170</pub-id></mixed-citation></ref><ref id="CR15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Smid</surname><given-names>A</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Svetic</surname><given-names>B</given-names></name><name><surname>Lenarcic</surname><given-names>B</given-names></name><name><surname>Vrhovec</surname><given-names>I</given-names></name><name><surname>Skrk</surname><given-names>J</given-names></name><name><surname>Turk</surname><given-names>V</given-names></name></person-group><article-title>Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer</article-title><source>Biol Chem Hoppe Seyler</source><year>1995</year><volume>376</volume><issue>7</issue><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">7576236</pub-id></mixed-citation></ref><ref id="CR16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Stabuc</surname><given-names>B</given-names></name><name><surname>Schweiger</surname><given-names>A</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Cimerman</surname><given-names>N</given-names></name><name><surname>Kopitar-Jerala</surname><given-names>N</given-names></name><name><surname>Vrhovec</surname><given-names>I</given-names></name></person-group><article-title>Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><issue>10</issue><fpage>1815</fpage><lpage>1822</lpage><pub-id pub-id-type="pmid">9815568</pub-id></mixed-citation></ref><ref id="CR17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><name><surname>Cimerman</surname><given-names>N</given-names></name><name><surname>Stephens</surname><given-names>RW</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name></person-group><article-title>Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><issue>6</issue><fpage>1511</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">9626470</pub-id></mixed-citation></ref><ref id="CR18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kos</surname><given-names>J</given-names></name><name><surname>Werle</surname><given-names>B</given-names></name><name><surname>Lah</surname><given-names>T</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name></person-group><article-title>Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer</article-title><source>Int J Biol Markers</source><year>2000</year><volume>15</volume><issue>1</issue><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">10763147</pub-id></mixed-citation></ref><ref id="CR19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lah</surname><given-names>TT</given-names></name><name><surname>Kokalj-Kunovar</surname><given-names>M</given-names></name><name><surname>Kastelic</surname><given-names>L</given-names></name><name><surname>Babnik</surname><given-names>J</given-names></name><name><surname>Stolfa</surname><given-names>A</given-names></name><name><surname>Rainer</surname><given-names>S</given-names></name><name><surname>Turk</surname><given-names>V</given-names></name></person-group><article-title>Cystatins and stefins in ascites fluid from ovarian carcinoma</article-title><source>Cancer Lett</source><year>1992</year><volume>61</volume><issue>3</issue><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/0304-3835(92)90295-7</pub-id><pub-id pub-id-type="pmid">1739949</pub-id></mixed-citation></ref><ref id="CR20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lah</surname><given-names>TT</given-names></name><name><surname>Strojnik</surname><given-names>T</given-names></name><name><surname>Levicar</surname><given-names>N</given-names></name><name><surname>Bervar</surname><given-names>A</given-names></name><name><surname>Zajc</surname><given-names>I</given-names></name><name><surname>Pilkington</surname><given-names>G</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors</article-title><source>Int J Biol Markers</source><year>2000</year><volume>15</volume><issue>1</issue><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">10763148</pub-id></mixed-citation></ref><ref id="CR21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landen</surname><given-names>CN</given-names><suffix>Jr</suffix></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name></person-group><article-title>Early events in the pathogenesis of epithelial ovarian cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>6</issue><fpage>995</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.9970</pub-id><pub-id pub-id-type="pmid">18195328</pub-id></mixed-citation></ref><ref id="CR22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leto</surname><given-names>G</given-names></name><name><surname>Tumminello</surname><given-names>FM</given-names></name><name><surname>Pizzolanti</surname><given-names>G</given-names></name><name><surname>Montalto</surname><given-names>G</given-names></name><name><surname>Soresi</surname><given-names>M</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name></person-group><article-title>Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications</article-title><source>Oncology</source><year>1997</year><volume>54</volume><issue>1</issue><fpage>79</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1159/000227666</pub-id><pub-id pub-id-type="pmid">8978598</pub-id></mixed-citation></ref><ref id="CR23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leto</surname><given-names>G</given-names></name><name><surname>Tumminello</surname><given-names>FM</given-names></name><name><surname>Pizzolanti</surname><given-names>G</given-names></name><name><surname>Montalto</surname><given-names>G</given-names></name><name><surname>Soresi</surname><given-names>M</given-names></name><name><surname>Carroccio</surname><given-names>A</given-names></name><name><surname>Ippolito</surname><given-names>S</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name></person-group><article-title>Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis</article-title><source>Pancreas</source><year>1997</year><volume>14</volume><issue>1</issue><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1097/00006676-199701000-00004</pub-id><pub-id pub-id-type="pmid">8981503</pub-id></mixed-citation></ref><ref id="CR24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindeman</surname><given-names>RD</given-names></name><name><surname>Goldman</surname><given-names>R</given-names></name></person-group><article-title>Anatomic and physiologic age changes in the kidney</article-title><source>Exp Gerontol</source><year>1986</year><volume>21</volume><issue>4&#x02013;5</issue><fpage>379</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1016/0531-5565(86)90044-6</pub-id><pub-id pub-id-type="pmid">3545873</pub-id></mixed-citation></ref><ref id="CR25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Tryggvason</surname><given-names>K</given-names></name><name><surname>Garbisa</surname><given-names>S</given-names></name><name><surname>Hart</surname><given-names>I</given-names></name><name><surname>Foltz</surname><given-names>CM</given-names></name><name><surname>Shafie</surname><given-names>S</given-names></name></person-group><article-title>Metastatic potential correlates with enzymatic degradation of basement membrane collagen</article-title><source>Nature</source><year>1980</year><volume>284</volume><issue>5751</issue><fpage>67</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/284067a0</pub-id><pub-id pub-id-type="pmid">6243750</pub-id></mixed-citation></ref><ref id="CR26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makarewicz</surname><given-names>R</given-names></name><name><surname>Drewa</surname><given-names>G</given-names></name><name><surname>Szymanski</surname><given-names>W</given-names></name><name><surname>Skonieczna-Makarewicz</surname><given-names>I</given-names></name></person-group><article-title>Cathepsin B in predicting the extent of the cervix carcinoma</article-title><source>Neoplasma</source><year>1995</year><volume>42</volume><issue>1</issue><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7617069</pub-id></mixed-citation></ref><ref id="CR27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Jaffe</surname><given-names>G</given-names></name></person-group><article-title>Age contrast in ovarian pathology</article-title><source>Cancer</source><year>1993</year><volume>71</volume><issue>Suppl 2</issue><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">8420674</pub-id></mixed-citation></ref><ref id="CR28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyake</surname><given-names>H</given-names></name><name><surname>Hara</surname><given-names>I</given-names></name><name><surname>Eto</surname><given-names>H</given-names></name></person-group><article-title>Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression</article-title><source>Anticancer Res</source><year>2004</year><volume>24</volume><issue>4</issue><fpage>2573</fpage><lpage>2577</lpage><pub-id pub-id-type="pmid">15330217</pub-id></mixed-citation></ref><ref id="CR29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulaomerovic</surname><given-names>A</given-names></name><name><surname>Halilbasic</surname><given-names>A</given-names></name><name><surname>Cickusic</surname><given-names>E</given-names></name><name><surname>Zavasnik-Bergant</surname><given-names>T</given-names></name><name><surname>Begic</surname><given-names>L</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma</article-title><source>Cancer Lett</source><year>2007</year><volume>248</volume><issue>2</issue><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2006.07.004</pub-id><pub-id pub-id-type="pmid">16945481</pub-id></mixed-citation></ref><ref id="CR30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Kawamata</surname><given-names>T</given-names></name><name><surname>Morimitsu</surname><given-names>K</given-names></name><name><surname>Kuwano</surname><given-names>M</given-names></name><name><surname>Miyakawa</surname><given-names>I</given-names></name></person-group><article-title>Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4</article-title><source>Gynecol Oncol</source><year>1995</year><volume>56</volume><issue>3</issue><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1006/gyno.1995.1063</pub-id><pub-id pub-id-type="pmid">7705668</pub-id></mixed-citation></ref><ref id="CR31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikawa</surname><given-names>H</given-names></name><name><surname>Ozaki</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Blomgren</surname><given-names>K</given-names></name><name><surname>Tada</surname><given-names>T</given-names></name><name><surname>Arakawa</surname><given-names>A</given-names></name><name><surname>Suzumori</surname><given-names>K</given-names></name></person-group><article-title>The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer</article-title><source>Gynecol Oncol</source><year>2004</year><volume>92</volume><issue>3</issue><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2003.11.017</pub-id><pub-id pub-id-type="pmid">14984956</pub-id></mixed-citation></ref><ref id="CR32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pecorelli</surname><given-names>S</given-names></name><name><surname>Benedet</surname><given-names>JL</given-names></name><name><surname>Creasman</surname><given-names>WT</given-names></name><name><surname>Shepherd</surname><given-names>JH</given-names></name></person-group><article-title>FIGO staging of gynecologic cancer. 1994&#x02013;1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics</article-title><source>Int J Gynaecol Obstet</source><year>1999</year><volume>65</volume><issue>3</issue><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S0020-7292(99)00070-3</pub-id><pub-id pub-id-type="pmid">10428343</pub-id></mixed-citation></ref><ref id="CR33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Premzl</surname><given-names>A</given-names></name><name><surname>Turk</surname><given-names>V</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro</article-title><source>J Cell Biochem</source><year>2006</year><volume>97</volume><issue>6</issue><fpage>1230</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1002/jcb.20720</pub-id><pub-id pub-id-type="pmid">16315320</pub-id></mixed-citation></ref><ref id="CR34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MK</given-names></name></person-group><article-title>Tissue cathepsins as tumor markers</article-title><source>Clin Chim Acta</source><year>1995</year><volume>237</volume><issue>1&#x02013;2</issue><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(95)06065-L</pub-id><pub-id pub-id-type="pmid">7664480</pub-id></mixed-citation></ref><ref id="CR35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>RE</given-names></name></person-group><article-title>Pathology of ovarian cancer precursors</article-title><source>J Cell Biochem Suppl</source><year>1995</year><volume>23</volume><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1002/jcb.240590928</pub-id><pub-id pub-id-type="pmid">8747398</pub-id></mixed-citation></ref><ref id="CR36"><mixed-citation publication-type="other">Servov SF, Scully RE, Sobin LH (1973) International histologic classification of tumors. No. 9: histologic typing of ovarian tumors. World Health Organization, Geneva, 1973</mixed-citation></ref><ref id="CR37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloane</surname><given-names>BF</given-names></name><name><surname>Moin</surname><given-names>K</given-names></name><name><surname>Krepela</surname><given-names>E</given-names></name><name><surname>Rozhin</surname><given-names>J</given-names></name></person-group><article-title>Cathepsin B and its endogenous inhibitors: the role in tumor malignancy</article-title><source>Cancer Metastasis Rev</source><year>1990</year><volume>9</volume><issue>4</issue><fpage>333</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1007/BF00049523</pub-id><pub-id pub-id-type="pmid">2097084</pub-id></mixed-citation></ref><ref id="CR38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stabuc</surname><given-names>B</given-names></name><name><surname>Vrhovec</surname><given-names>L</given-names></name><name><surname>Stabuc-Silih</surname><given-names>M</given-names></name><name><surname>Cizej</surname><given-names>TE</given-names></name></person-group><article-title>Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy</article-title><source>Clin Chem</source><year>2000</year><volume>46</volume><issue>2</issue><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">10657375</pub-id></mixed-citation></ref><ref id="CR39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strojan</surname><given-names>P</given-names></name><name><surname>Budihna</surname><given-names>M</given-names></name><name><surname>Smid</surname><given-names>L</given-names></name><name><surname>Svetic</surname><given-names>B</given-names></name><name><surname>Vrhovec</surname><given-names>I</given-names></name><name><surname>Skrk</surname><given-names>J</given-names></name></person-group><article-title>Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck</article-title><source>Neoplasma</source><year>2001</year><volume>48</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">11327540</pub-id></mixed-citation></ref><ref id="CR40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strojan</surname><given-names>P</given-names></name><name><surname>Svetic</surname><given-names>B</given-names></name><name><surname>Smid</surname><given-names>L</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Serum cystatin C in patients with head and neck carcinoma</article-title><source>Clin Chim Acta</source><year>2004</year><volume>344</volume><issue>1&#x02013;2</issue><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cccn.2004.02.011</pub-id><pub-id pub-id-type="pmid">15149884</pub-id></mixed-citation></ref><ref id="CR41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turk</surname><given-names>B</given-names></name><name><surname>Turk</surname><given-names>D</given-names></name><name><surname>Turk</surname><given-names>V</given-names></name></person-group><article-title>Lysosomal cysteine proteases: more than scavengers</article-title><source>Biochim Biophys Acta</source><year>2000</year><volume>1477</volume><issue>1&#x02013;2</issue><fpage>98</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">10708852</pub-id></mixed-citation></ref><ref id="CR42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warwas</surname><given-names>M</given-names></name><name><surname>Haczynska</surname><given-names>H</given-names></name><name><surname>Gerber</surname><given-names>J</given-names></name><name><surname>Nowak</surname><given-names>M</given-names></name></person-group><article-title>Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma</article-title><source>Eur J Clin Chem Clin Biochem</source><year>1997</year><volume>35</volume><issue>4</issue><fpage>301</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">9166974</pub-id></mixed-citation></ref><ref id="CR43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>M</given-names></name></person-group><article-title>Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation</article-title><source>Int J Gynecol Pathol</source><year>2004</year><volume>23</volume><issue>4</issue><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1097/01.pgp.0000139636.94352.89</pub-id><pub-id pub-id-type="pmid">15381900</pub-id></mixed-citation></ref><ref id="CR44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Hirai</surname><given-names>K</given-names></name><name><surname>Naito</surname><given-names>Z</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Ishiwata</surname><given-names>T</given-names></name><name><surname>Shiraki</surname><given-names>Y</given-names></name><name><surname>Inokuchi</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>G</given-names></name></person-group><article-title>Expression of cathepsin B and cystatin C in human breast cancer</article-title><source>Surg Today</source><year>2001</year><volume>31</volume><issue>5</issue><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1007/s005950170126</pub-id><pub-id pub-id-type="pmid">11381499</pub-id></mixed-citation></ref><ref id="CR45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zore</surname><given-names>I</given-names></name><name><surname>Krasovec</surname><given-names>M</given-names></name><name><surname>Cimerman</surname><given-names>N</given-names></name><name><surname>Kuhelj</surname><given-names>R</given-names></name><name><surname>Werle</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>HJ</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Kos</surname><given-names>J</given-names></name></person-group><article-title>Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer</article-title><source>Biol Chem</source><year>2001</year><volume>382</volume><issue>5</issue><fpage>805</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1515/BC.2001.097</pub-id><pub-id pub-id-type="pmid">11517934</pub-id></mixed-citation></ref></ref-list></back></article>